VAXX News and Press, Vaxxinity Inc. From 10/24/22

UB-612 Phase 3 topline data readout expected in 4Q22 DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that enrollment is complete for its global Phase 3...

DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin ge...

Vaxxinity ( NASDAQ: VAXX ) on Monday said it had started a rolling submission to UK's drug regulator for conditional marketing approval of its UB-612 COVID-19 vaccine for use as a booster dose. The shot is currently being evaluated in a phase 3 trial as a booster dose for ...

DALLAS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it has initiated a rolling submission to the Medicines and Healthcare products Regulatory Agency (MHRA) in ...

DALLAS, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present at the following investor conferences in Sep...

Vaxxinity press release ( NASDAQ: VAXX ): Q2 GAAP EPS of -$0.14 beats by $0.24 . As of June 30, 2022, cash and cash equivalents were $109.1 million, as compared to $144.9 million on December 31, 2021. Shares +1.28% PM. For further details see: Vaxxini...

• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312 Phase 1 Part B Trial for Parkinson’s Completes Last Patient Last Dose, and Remains on Track to Complete an End-of-Treatment Analysis in the Sec...

DALLAS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present at the Canaccord Genuity 42 nd ...

Results support Anti-PCSK9 vaccine approach to treat hypercholesterolemia by lowering LDL cholesterol VXX-401 selected as Lead Candidate to treat hypercholesterolemia DALLAS, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the ...

DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (...